Trial reportSurgical endoscopy2018
Effect of premedication on lesion detection rate and visualization of the mucosa during upper gastrointestinal endoscopy: a multicenter large sample randomized controlled double-blind study.
Trial report in Surgical endoscopy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Asian Pacific Association of Gastroenterology task force recommendations on surveillance forGut · 2026Guideline
- The effect of using simethicone with or without N-acetylcysteine before gastroscopy: A meta-analysis and systemic review.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology AssociationPooled it
- The Effect of Using Premedication of Simethicone/Pronase With or Without Postural Change on Visualization of the Mucosa Before Endoscopy: A Prospective, Double Blinded, Randomized Controlled Trial.Clinical and translational gastroenterology · 2024Trial
- Pre-procedure oral administration of pronase improves efficacy of lugol chromoendoscopy in esophageal squamous cell carcinoma screening: a prospective, double-blinded, randomized, controlled trial.Surgical endoscopy · 2023Trial
- Premedication with reformulated simethicone and sodium bicarbonate improves mucosal visibility during upper gastrointestinal endoscopy: a double-blind, multicenter, randomized controlled trial.BMC gastroenterology · 2021Trial
- A prospective randomized controlled trial comparing simethicone, N-acetylcysteine, sodium bicarbonate and peppermint for visualization in upper gastrointestinal endoscopy.Surgical endoscopy · 2021Trial
- The impact of photographic image quantity on early upper gastrointestinal cancer detection during esophagogastroduodenoscopy.Scientific reports · 2025Article
- Consensus on Upper Gastrointestinal Endoscopy Key Performance Indicators to Reduce Post Endoscopy Upper Gastrointestinal Cancer.United European gastroenterology journal · 2025Article
- How to improve the quality of upper gastrointestinal diagnostic endoscopy?Clinical endoscopy · 2025Review
- Research and experiments of a new premedication for improving mucosal visibility during esophagogastroduodenoscopy.BMC gastroenterology · 2025Article
- Summary of gastroscopy quality indicators applicable in clinical practice.Przeglad gastroenterologiczny · 2025Review
- Positioning exercises in improving the quality of magnetic-controlled capsule endoscopy.BMC gastroenterology · 2024Article
- Umbrella systematic review of potential quality indicators for the detection of dysplasia and cancer at upper gastrointestinal endoscopy.Endoscopy international open · 2023Review
- Inadequate gastric preparation and its associated factors for magnetically controlled capsule endoscopy.Frontiers in pharmacology · 2023Article
- Chinese integrated guideline on the management of gastric precancerous conditions and lesions.Chinese medicine · 2022Review
- Premedication with simethicone for improving the quality of gastric mucosal visualization: a double-blind randomized controlled trial.Endoscopy international open · 2022Article
- Quality indicators in esophagogastroduodenoscopy.Clinical endoscopy · 2022Review
- Diagnostic Value of Endoscopic Narrow-Band Imaging Technique in Early Gastric Cancer and Precancerous Lesions.Scanning · 2022Article
- Does Premedication with Mucolytic Agents Improve Mucosal Visualization during Oesophagogastroduodenoscopy: A Systematic Review and Meta-Analysis.Surgery research and practice · 2021Review
- Quality indicators in diagnostic upper gastrointestinal endoscopy.Therapeutic advances in gastroenterology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPremedication in upper gastrointestinal endoscopy for higher lesions detection rate has not been well studied so far. This study aimed to confirm whether premedication could improve the detection rate of early cancer or precancerous lesions and mucosal visibility.
methodFrom July 2015 to December 2015, 7200 participants from 6 centers were screened by endoscopy with one of the 4 following premedications randomly: (1) water (group D); (2) pronase (group A); (3) simethicone (group B); (4) pronase and simethicone (group C). Early cancer and precancerous lesions detection rates were taken as the primary endpoints, and mucosal visibility was taken as the secondary endpoint. They were compared among four groups to determine different premedication effects in terms of different anatomical sites. Trial was registered at Chinese Clinical Trial Registry; the registration number is ChiCTR-IOR-17010985.
resultsThe upper gastrointestinal overall precancerous lesion detection rates among four groups were 8.7, 8.4, 10.0, and 10.3%, the overall early cancer detection rates were 1.3, 1.4%, 1.5, and 1.6%, both without significant difference (p = 0.138 and 0.878). However, the visibility score distributions between control group (D) and premedication groups (A, B, and C) were all statistically significant, with all anatomical sites p values < 0.001. Subgroup analyses, from 2 centers without screening before, also showed significant difference in esophageal (3.9, 3.3, 4.5, and 8.4% with p = 0.004) and overall (7.0, 5.5, 7.3, and 12.0% with p = 0.004) precancerous lesion detection rate.
conclusionsPremedication with pronase and simethicone may not increase lesion detection rates but could significantly increase the upper gastrointestinal mucosal visibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.